Under a tenth of patients eligible to benefit from obesity jabs including Wegovy have access to them, warns the WHO as it issues its inaugural recommendations on the therapies.
Given over a billion people worldwide currently living with obesity, it is calling for increased and just access to these injectable treatments.
According to estimates, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The latest guidance acknowledges that obesity is a lifelong illness that can be treated with comprehensive and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant barriers to broad access to the treatments that can assist patients in reducing substantial body mass, notes the organization.
Weight-Loss Drug Supply Crisis
Despite the current best projected outlook, the production of GLP-1 therapies could only cover around 100 million people – less than 10% of the global need, as stated by the WHO.
The recommendation calls on nations and manufacturers to expand access, via strategies including licensing agreements.
The intellectual property rights on a key compound – the core component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Injections Operate
The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so individuals eat less.
Individuals typically begin shedding pounds after several weeks of beginning the weekly injections.
Studies points to patients may put most of the weight back on within a year of stopping the drug, because their normal food cravings come back.
To be overweight or obese raises your likelihood for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity affects individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, as per the WHO.
